CINECA IRIS Institutional Research Information System

BONORA, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.090
EU - Europa 12.195
AS - Asia 6.068
SA - Sud America 371
AF - Africa 278
OC - Oceania 78
Continente sconosciuto - Info sul continente non disponibili 25
Totale 39.105
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.751
CN - Cina 3.063
IT - Italia 2.165
DK - Danimarca 1.826
IE - Irlanda 1.303
DE - Germania 1.238
SG - Singapore 1.232
SE - Svezia 1.064
FR - Francia 1.035
FI - Finlandia 722
UA - Ucraina 722
GB - Regno Unito 597
KR - Corea 523
AT - Austria 355
PL - Polonia 300
VN - Vietnam 258
IN - India 242
CA - Canada 226
ID - Indonesia 194
NL - Olanda 188
ES - Italia 185
BR - Brasile 174
JP - Giappone 127
ZA - Sudafrica 120
MX - Messico 91
RO - Romania 84
TW - Taiwan 81
BE - Belgio 80
RU - Federazione Russa 76
TH - Thailandia 70
AU - Australia 68
CH - Svizzera 65
HK - Hong Kong 59
AR - Argentina 51
TR - Turchia 49
CO - Colombia 43
CL - Cile 42
PE - Perù 42
CZ - Repubblica Ceca 38
PK - Pakistan 35
GR - Grecia 30
PT - Portogallo 28
IR - Iran 25
EU - Europa 22
IL - Israele 22
UZ - Uzbekistan 19
PH - Filippine 18
NG - Nigeria 17
UG - Uganda 17
KE - Kenya 16
HR - Croazia 15
ET - Etiopia 14
SN - Senegal 14
EG - Egitto 12
BG - Bulgaria 11
SK - Slovacchia (Repubblica Slovacca) 11
HU - Ungheria 10
NZ - Nuova Zelanda 10
EC - Ecuador 9
NO - Norvegia 9
SA - Arabia Saudita 8
TZ - Tanzania 8
AE - Emirati Arabi Uniti 7
LT - Lituania 7
MU - Mauritius 7
MY - Malesia 7
LV - Lettonia 6
MW - Malawi 6
SD - Sudan 6
TN - Tunisia 6
DZ - Algeria 5
RS - Serbia 5
BO - Bolivia 4
CR - Costa Rica 4
CU - Cuba 4
GH - Ghana 4
JO - Giordania 4
MZ - Mozambico 4
NA - Namibia 4
BY - Bielorussia 3
CD - Congo 3
CM - Camerun 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GT - Guatemala 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MD - Moldavia 3
PA - Panama 3
PR - Porto Rico 3
VE - Venezuela 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
BJ - Benin 2
BT - Bhutan 2
GA - Gabon 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
LI - Liechtenstein 2
LK - Sri Lanka 2
Totale 39.073
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.773
Beijing 2.202
Chandler 1.952
Dublin 1.298
Houston 1.188
Singapore 975
Fairfield 881
Santa Clara 778
Ashburn 712
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 529
Dearborn 479
Medford 469
Princeton 441
Woodbridge 431
Redwood City 384
Columbus 358
Seattle 354
Nyköping 314
Vienna 299
Warsaw 286
Cambridge 268
Milan 194
Pisa 185
Turin 169
Boston 142
New York 135
Fremont 130
Jakarta 130
Dong Ket 116
Boardman 115
Guangzhou 107
Toronto 84
Shanghai 78
Verona 75
Nanjing 66
San Diego 64
Paris 63
Helsinki 57
Munich 57
Brussels 54
Hangzhou 54
Norwalk 52
Taipei 51
Rome 50
Hefei 49
Kunming 48
Los Angeles 45
São Paulo 44
Cape Town 38
Nürnberg 38
Washington 38
Chicago 37
Falls Church 35
Lima 35
London 33
Ottawa 33
Pune 33
Santiago 32
Hong Kong 30
Jinan 30
Phoenix 30
Buenos Aires 28
Chengdu 28
Seoul 28
Mountain View 27
Omaha 26
Silver Spring 26
Bengaluru 25
Frankfurt am Main 24
Montreal 24
Brno 23
Lachine 23
Zhengzhou 23
Buffalo 22
Dallas 22
Arlington 21
Hebei 21
Tokyo 21
Hanoi 20
Barcelona 19
Changsha 19
Madrid 19
Upper Marlboro 19
Amsterdam 18
Des Moines 18
Tariceni 18
Toulouse 18
Wuhan 18
Mumbai 17
Atlanta 16
Copenhagen 16
Duncan 16
Minneapolis 16
Nanchang 16
New Delhi 16
Shenyang 16
Bangkok 15
Totale 23.746
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 814
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 717
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 610
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 509
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 439
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 421
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 389
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 383
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 354
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 328
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 318
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 313
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 312
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 301
Heart failure in patients with human immunodeficiency virus: a review of the literature. 300
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 287
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 286
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 284
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 264
Raltegravir penetration in seminal plasma of healthy volunteers. 256
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 254
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 244
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 242
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 239
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 237
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 234
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 232
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 230
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 225
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 211
Prevalence and predictors of blood-brain barrier damage in the HAART era. 210
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 206
Acute HIV infection: Improved algorithms for HIV testing. 205
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 203
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 202
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 194
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 194
Cardiovascular disease in HIV patients: from bench to bedside and backwards 182
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 181
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 181
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 181
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 180
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 180
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 177
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 177
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 176
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 175
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 173
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 173
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 171
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 171
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 170
Failure of prophylaxis against PCP in patients with HIV infection. 169
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 166
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 164
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 164
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 163
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 162
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 162
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 161
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 161
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 160
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 160
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 160
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 158
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 158
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 157
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 157
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 156
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 156
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 155
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 154
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 154
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 154
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 154
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 152
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 152
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 152
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 150
What do we know about tailoring treatment with tenofovir? 150
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 149
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 149
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 149
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 148
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 147
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 147
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 146
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 145
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 145
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 145
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 145
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 144
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 144
Continuous intravenous infusion of enfuvirtide in an out-clinic patient with a multi resistent HIV strain and severe injection-site reactions 144
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 143
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 143
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 142
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 141
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 141
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 137
Totale 21.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.413
article - articoli 0
book - libri 0
conference - conferenze 21.574
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.987
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.817 0 0 0 0 0 1.419 649 358 411 575 658 747
2020/20214.466 615 197 249 246 404 359 323 159 447 371 316 780
2021/20226.295 540 453 545 604 429 439 562 512 352 256 714 889
2022/20236.212 631 368 123 579 651 1.584 462 455 676 122 330 231
2023/20242.828 355 457 158 159 240 402 78 180 55 119 233 392
2024/20253.217 117 318 306 648 1.621 207 0 0 0 0 0 0
Totale 40.777